Mersana Therapeutics, Inc. (MRSN): Price and Financial Metrics


Mersana Therapeutics, Inc. (MRSN): $11.62

0.01 (+0.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRSN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

MRSN POWR Grades


  • MRSN scores best on the Momentum dimension, with a Momentum rank ahead of 34.68% of US stocks.
  • The strongest trend for MRSN is in Growth, which has been heading down over the past 31 weeks.
  • MRSN ranks lowest in Sentiment; there it ranks in the 6th percentile.

MRSN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MRSN is 0 -- better than only 8.03% of US stocks.
  • MRSN's price/sales ratio is 998.54; that's higher than the P/S ratio of 99.17% of US stocks.
  • Mersana Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -27.93%, greater than the shareholder yield of just 10.09% of stocks in our set.
  • Stocks that are quantitatively similar to MRSN, based on their financial statements, market capitalization, and price volatility, are GERN, EDSA, AIM, CKPT, and CRDF.
  • Visit MRSN's SEC page to see the company's official filings. To visit the company's web site, go to www.mersana.com.

MRSN Valuation Summary

  • In comparison to the median Healthcare stock, MRSN's EV/EBIT ratio is 121.72% lower, now standing at -5.8.
  • Over the past 50 months, MRSN's price/sales ratio has gone up 986.3.
  • MRSN's EV/EBIT ratio has moved up 8.1 over the prior 50 months.

Below are key valuation metrics over time for MRSN.

Stock Date P/S P/B P/E EV/EBIT
MRSN 2021-02-16 1759.4 6.0 -20.1 -16.8
MRSN 2019-05-10 6.3 2.5 -10.2 -5.8
MRSN 2018-11-12 8.1 3.0 -2.9 -1.8
MRSN 2018-06-25 27.9 8.1 -10.6 -9.8
MRSN 2017-12-06 13.9 4.3 -21.9 -18.8
MRSN 2017-08-04 13.2 -5.4 -20.7 -15.3

MRSN Price Target

For more insight on analysts targets of MRSN, see our MRSN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $28.75 Average Broker Recommendation 1.25 (Strong Buy)

MRSN Stock Price Chart Interactive Chart >

Price chart for MRSN

MRSN Price/Volume Stats

Current price $11.62 52-week high $29.09
Prev. close $11.61 52-week low $11.25
Day low $11.25 Volume 478,791
Day high $11.70 Avg. volume 796,699
50-day MA $13.65 Dividend yield N/A
200-day MA $18.37 Market Cap 808.31M

Mersana Therapeutics, Inc. (MRSN) Company Bio


Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.


MRSN Latest News Stream


Event/Time News Detail
Loading, please wait...

MRSN Latest Social Stream


Loading social stream, please wait...

View Full MRSN Social Stream

Latest MRSN News From Around the Web

Below are the latest news stories about Mersana Therapeutics Inc that investors may wish to consider to help them evaluate MRSN as an investment opportunity.

Is Mersana Therapeutics, Inc. (MRSN) A Good Stock To Buy?

While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious towards the current bull run since March, 2020 and hedging or reducing many of their long positions. Some fund managers are betting on Dow […]

Yahoo | July 13, 2021

The Bottom Is in for These 2 Stocks? Analysts Say ‘Buy’

When stocks hit bottom, investors should take note. Stock prices fall for a reason, but those reasons don’t always mean that the stock is unsound. In fact, some fundamentally strong equities can fall to rock bottom prices – and when that happens, it’s a buying opportunity. Wall Street’s analysts are frequently on the alert for these cases, as they generally offer investors some of the best upside potentials in the market. Using TipRanks' database, we pinpointed two stocks whose price has fallen low – but in these cases, the analysts see the low price as a gateway.

Michael Marcus on TipRanks | June 29, 2021

New Strong Sell Stocks for May 28th

ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021

Yahoo | May 28, 2021

Mersana Therapeutics to Present at Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:00 a.m. ET. A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and t...

Yahoo | May 26, 2021

Is MRSN Stock A Buy or Sell?

The Insider Monkey team has completed processing the quarterly 13F filings for the December quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

Yahoo | April 19, 2021

Read More 'MRSN' Stories Here

MRSN Price Returns

1-mo -17.30%
3-mo -30.38%
6-mo -37.63%
1-year -43.78%
3-year 4.87%
5-year N/A
YTD -56.33%
2020 364.40%
2019 40.44%
2018 -75.17%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.902 seconds.